IDEAYA Biosciences, Inc. (IDYA) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$38.88

From 52W high−9.58%

Volume2.45M

Market cap$3.71B

P/E (TTM)—

P/S (TTM)15.8x

Div yield—

Key dataSep 18, 2026

Open

$38.88

From 52W high

−9.58%

Volume

2.45M

Market cap

$3.71B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−13.7x

P/E (TTM)

—

RSI (14)

48.9

MomentumView details →

1D Return

−0.52%

YTD Return

+10.65%

SummaryUpdated Jun 1, 2026

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is a precision medicine oncology company founded in 2015 and headquartered in South San Francisco, California. The company went public in May 2019 and focuses on developing targeted cancer therapeutics using a synthetic lethality approach. IDEAYA identifies specific genetic vulnerabilities in cancer cells and develops drugs that exploit these weaknesses while sparing healthy cells. The company currently has multiple drug candidates in clinical trials and maintains strategic partnerships with major pharmaceutical companies including Pfizer and GlaxoSmithKline.

Ask drillr about IDEAYA Biosciences, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−13.7x

EV/Sales

12.4x

P/S (TTM)

15.8x

P/B (TTM)

3.1x

ProfitabilityView details →

Gross Margin

−13.32%

Net Margin

−74.75%

EBITDA Margin

−90.75%

ROE (TTM)

−14.60%

ROA (TTM)

−13.36%

Asset Turnover

0.20x

GrowthView details →

Revenue YoY

+3244.67%

EPS YoY

+49.34%

FCF YoY

+36.08%

Revenue CAGR 3Y

+62.54%

EPS CAGR 3Y

+61.90%

EBITDA YoY

+37.20%

MomentumView details →

1D Return

−0.52%

YTD Return

+10.65%

1Y Return

+48.60%

RSI (14)

48.9

vs 50D SMA

+1.62%

vs 200D SMA

+12.85%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

10.45x

Quick Ratio

10.45x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.22

EPS Surprise

−15.09%

Beats (12Q)

3/12

Next Q EPS Est

−$1.18

Avg Surprise (4Q)

−33.12%

Rev Surprise

10.44%

Financials snapshotView financials →

Revenue (TTM)

234.13M

Net Income (TTM)

−175.02M

Op. CF (TTM)

−186.83M

Next earningsNov 9, 2026 →

Latest newsMore news →

IDEAYA Biosciences reported financial results for the second quarter ended June 30, 2026, with cash and marketable securities of approximately $1.24 billion as of that date.47d ago

Similar companies

Qyuns Therapeutics Co., Ltd.02509.HK Tango Therapeutics, Inc.TNGX Mirxes Holding Company Limited02629.HK Tarsus Pharmaceuticals, Inc.TARS Enliven Therapeutics, Inc.ELVN Xenon Pharmaceuticals Inc.XENE Find similar companies →

Latest newsMore news →

IDEAYA Biosciences entered into a clinical collaboration with Genentech to evaluate IDE892 in combination with RG6620 in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma, with Genentech sponsoring the trial and joint governance overseeing the study.32d ago IDEAYA Biosciences reported financial results for the second quarter ended June 30, 2026, with cash and marketable securities of approximately $1.24 billion as of that date.47d ago